JPH10206995A - Silver halide photographic sensitive material - Google Patents
Silver halide photographic sensitive materialInfo
- Publication number
- JPH10206995A JPH10206995A JP866897A JP866897A JPH10206995A JP H10206995 A JPH10206995 A JP H10206995A JP 866897 A JP866897 A JP 866897A JP 866897 A JP866897 A JP 866897A JP H10206995 A JPH10206995 A JP H10206995A
- Authority
- JP
- Japan
- Prior art keywords
- silver halide
- silver
- solution
- emulsion
- grains
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明はハロゲン化銀写真感
光材料に関し、詳しくは、特定の硫黄化合物によって化
学増感された、高感度でカブリが少なく、かつ保存時の
写真特性変動が改良されたハロゲン化銀写真感光材料
(以下、「感光材料」とも称す)に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a silver halide photographic light-sensitive material, and more particularly to a silver halide photographic material which is chemically sensitized by a specific sulfur compound, has high sensitivity, has low fog, and has improved photographic characteristics during storage. The present invention relates to a silver halide photographic material (hereinafter, also referred to as a "photosensitive material").
【0002】[0002]
【従来の技術】通常、ハロゲン化銀乳剤(以下、「乳
剤」とも称す)には、感度を高めるために各種の化学増
感処理が施される。その代表的方法の一つとして、乳剤
層中に微量の硫黄又は硫黄化合物を添加し、硫化銀を生
成せしめて感度を増加する方法は硫黄増感法として知ら
れており、化学増感法の中でも最も基本的なものであ
る。又、適当な還元剤を用いる還元増感法、金やイリジ
ウム等の貴金属を用いる貴金属増感法なども知られてい
る。更に、これらの増感法を組み合わせることにより、
乳剤の感度をより増加させ得ることも公知である。2. Description of the Related Art Usually, silver halide emulsions (hereinafter, also referred to as "emulsions") are subjected to various chemical sensitization treatments in order to increase sensitivity. As one of the typical methods, a method of increasing the sensitivity by adding a small amount of sulfur or a sulfur compound to an emulsion layer to generate silver sulfide is known as a sulfur sensitization method. The most basic of them. Also, a reduction sensitization method using an appropriate reducing agent, a noble metal sensitization method using a noble metal such as gold or iridium, and the like are known. Furthermore, by combining these sensitization methods,
It is also known that the sensitivity of emulsions can be further increased.
【0003】硫黄増感法としては、例えば米国特許2,
410,689号、同3,501,313号、西ドイツ
特許1,422,869号、特公昭49−20533
号、特開昭55−45016号等に記載されている。As a sulfur sensitization method, for example, US Pat.
410,689, 3,501,313, West German Patent 1,422,869, JP-B-49-20533.
And JP-A-55-45016.
【0004】近年、感光材料には、処理時間の短縮化と
塗布銀量の削減が指向されており、これに伴いハロゲン
化銀乳剤の一層の高感度化が求められるようになった。In recent years, there has been an increasing demand for light-sensitive materials to reduce the processing time and the amount of coated silver, and accordingly, it has been required to further increase the sensitivity of silver halide emulsions.
【0005】硫黄増感法の中でも、特開昭55−450
16号に記載の増感技術は公知の硫黄増感法に比べ、増
感効果の大きいものである。[0005] Among the sulfur sensitization methods, JP-A-55-450 discloses
The sensitizing technique described in No. 16 has a larger sensitizing effect than the known sulfur sensitizing method.
【0006】しかしながら、これらの増感技術はカブリ
を伴う傾向があり、又、経時保存した際にカブリが発生
して写真特性に変化が生じる欠点が見られ、十分満足す
べき技術とは言えない現状にある。However, these sensitizing techniques tend to be accompanied by fogging, and have a drawback that fogging occurs when stored over time, causing a change in photographic properties, and cannot be said to be a technique that is sufficiently satisfactory. In the current situation.
【0007】[0007]
【発明が解決しようとする課題】従って本発明の目的
は、カブリを伴わずに感度が高められ、しかも保存安定
性に優れたハロゲン化銀写真感光材料を提供することに
ある。SUMMARY OF THE INVENTION Accordingly, an object of the present invention is to provide a silver halide photographic light-sensitive material whose sensitivity is improved without fogging and which has excellent storage stability.
【0008】[0008]
【課題を解決するための手段】本発明の上記目的は、下
記構成により達成された。The above objects of the present invention have been attained by the following constitutions.
【0009】支持体上に少なくとも1層の感光性ハロゲ
ン化銀乳剤層を有するハロゲン化銀写真感光材料におい
て、該ハロゲン化銀乳剤層の少なくとも1層が、下記一
般式(I)で示される化合物の少なくとも1種によって
増感されたハロゲン化銀粒子を含むことを特徴とするハ
ロゲン化銀写真感光材料。In a silver halide photographic material having at least one light-sensitive silver halide emulsion layer on a support, at least one of the silver halide emulsion layers is a compound represented by the following formula (I): A silver halide photographic material comprising silver halide grains sensitized by at least one of the following.
【0010】[0010]
【化2】 Embedded image
【0011】式中、Aはメルカプト基が置換した含窒素
複素環残基、環構成原子として窒素原子を4〜5個含む
含窒素複素環残基、トリアジン環残基又はベンゾトリア
ゾール環残基を表し、R1、R2及びR3は各々、水素原
子、アルキル基、アルケニル基、アルキニル基、アリー
ル基又は複素環基を表す。又、R2とR3が結合して複素
環を形成してもよい。In the formula, A is a nitrogen-containing heterocyclic residue substituted with a mercapto group, a nitrogen-containing heterocyclic residue containing 4 to 5 nitrogen atoms as ring constituent atoms, a triazine ring residue or a benzotriazole ring residue. And R 1 , R 2 and R 3 each represent a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, an aryl group or a heterocyclic group. R 2 and R 3 may combine to form a heterocyclic ring.
【0012】以下、本発明をより具体的に説明する。Hereinafter, the present invention will be described more specifically.
【0013】まず、上記一般式(I)で示される化合物
について説明する。First, the compound represented by formula (I) will be described.
【0014】一般式(I)において、Aが表すメルカプ
ト基が置換した含窒素複素環残基としては、例えばメル
カプトテトラゾール、メルカプトトリアゾール、メルカ
プトオキサゾール、メルカプトチアゾール、メルカプト
ベンゾセレナゾール、メルカプトチアジアゾール、メル
カプトオキサジアゾール、メルカプトトリアジン、メル
カプトベンゾオキサゾール、メルカプトベンゾチアゾー
ル、メルカプトベンズイミダゾール、メルカプトアデニ
ン、メルカプトグアニン等の各環残基が挙げられる。In the general formula (I), examples of the nitrogen-containing heterocyclic residue substituted by the mercapto group represented by A include mercaptotetrazole, mercaptotriazole, mercaptooxazole, mercaptothiazole, mercaptobenzoselenazole, mercaptothiadiazole, and mercaptooxadiazole. Each ring residue such as diazole, mercaptotriazine, mercaptobenzoxazole, mercaptobenzothiazole, mercaptobenzimidazole, mercaptoadenine, mercaptoguanine and the like can be mentioned.
【0015】Aが表す、環構成原子として窒素原子を4
〜5個含む含窒素複素環残基としては、例えばテトラゾ
ール、テトラザインデン、アデニン、アザアデニン、グ
アニン等の各環残基が挙げられる。A represents 4 nitrogen atoms as ring constituent atoms.
Examples of the nitrogen-containing heterocyclic residue containing up to 5 include each ring residue such as tetrazole, tetrazaindene, adenine, azaadenine, and guanine.
【0016】Aは又、トリアジン環残基又はベンゾトリ
アゾール環残基を表す。A also represents a triazine ring residue or a benzotriazole ring residue.
【0017】Aで表されるこれらの複素環残基は、アル
キル基、アルコキシ基、アリール基、ヒドロキシル基、
カルボキシル基、ハロゲン原子等、種々の置換基で置換
されてもよい。These heterocyclic residues represented by A include an alkyl group, an alkoxy group, an aryl group, a hydroxyl group,
It may be substituted with various substituents such as a carboxyl group and a halogen atom.
【0018】R1、R2及びR3が表すアルキル基として
は、メチル、エチル、プロピル、i−プロピル、ブチ
ル、i−ブチル、sec−ブチル等の基が挙げられ、ア
ルケニル基としては、アリル、クロチル等の基が挙げら
れ、アルキニル基としては、プロパルギル等の基が挙げ
られる。又、アリール基としては、フェニル、ナフチル
等の基が挙げられ、複素環基としては、オキサゾリル、
チアゾリル、ピリジル、ピリミジニル等の基が挙げられ
る。Examples of the alkyl group represented by R 1 , R 2 and R 3 include methyl, ethyl, propyl, i-propyl, butyl, i-butyl and sec-butyl, and the alkenyl group is allyl. , Crotyl and the like, and the alkynyl group includes a group such as propargyl. Examples of the aryl group include groups such as phenyl and naphthyl, and examples of the heterocyclic group include oxazolyl,
Groups such as thiazolyl, pyridyl and pyrimidinyl;
【0019】R2とR3が結合して形成することができる
複素環としては、ピロリジン、ピペラジン、ピペリジ
ン、モルホリン等の環を挙げることができる。The heterocyclic ring which can be formed by combining R 2 and R 3 includes rings such as pyrrolidine, piperazine, piperidine and morpholine.
【0020】R1、R2、R3が表すアルキル基、アルケ
ニル基、アルキニル基、アリール基又は複素環基及びR
2とR3が結合して形成する複素環は、更に置換基を有し
てもよく、該置換基としてはアルキル基、ヒドロキシル
基、アルコキシ基、カルボキシル基、アリール基やハロ
ゲン原子が挙げられる。The alkyl, alkenyl, alkynyl, aryl or heterocyclic groups represented by R 1 , R 2 and R 3 and R
Heterocycle 2 and R 3 are formed by bonding may further have a substituent, examples of the substituent include an alkyl group, a hydroxyl group, an alkoxy group, a carboxyl group, an aryl group or a halogen atom.
【0021】以下に、一般式(I)で示される化合物
(本発明の硫黄化合物という)の具体例を挙げるが、こ
れに限定されない。Hereinafter, specific examples of the compound represented by formula (I) (referred to as the sulfur compound of the present invention) will be given, but the invention is not limited thereto.
【0022】[0022]
【化3】 Embedded image
【0023】[0023]
【化4】 Embedded image
【0024】[0024]
【化5】 Embedded image
【0025】[0025]
【化6】 Embedded image
【0026】[0026]
【化7】 Embedded image
【0027】次に、上記硫黄化合物の合成例を示す。Next, a synthesis example of the above sulfur compound will be described.
【0028】合成例1(例示化合物1の合成) 1−(3−アミノフェニル)−5−メルカプトテトラゾ
ール塩酸塩2.18g、エチルイソチオシアナート0.
87g、トリエチルアミン1,01gをアセトニトリル
50mlに加え、15時間還流した。反応物を25ml
まで濃縮し、水50mlを加えて沈澱させ、濾過、水洗
する。濾取したケーキを水50ml中に入れ、塩酸2m
lを加えて90℃まで加熱し、10分保温後70℃に冷
却し、濾過、水洗する。ケーキをアセトニトリル60m
lに70℃で溶解し、冷却後、若干の不溶物を濾別す
る。濾液に水50mlを加えて暫く放置すると固体が析
出するので濾取し、ケーキを60℃で減圧乾燥し、目的
物1.7g(60%収率)を得た。Synthesis Example 1 (Synthesis of Exemplified Compound 1) 1.18 g of 1- (3-aminophenyl) -5-mercaptotetrazole hydrochloride, ethyl isothiocyanate 0.1 g
87 g and 1,01 g of triethylamine were added to 50 ml of acetonitrile, and the mixture was refluxed for 15 hours. 25 ml of reaction product
The mixture is concentrated to 50 ml, precipitated by adding 50 ml of water, filtered and washed with water. The cake collected by filtration is put into 50 ml of water, and 2 m of hydrochloric acid is added.
Then, the mixture is heated to 90 ° C., kept warm for 10 minutes, cooled to 70 ° C., filtered and washed with water. Cake is acetonitrile 60m
and cooled at 70 ° C., and after cooling, some insolubles are filtered off. After adding 50 ml of water to the filtrate and leaving it for a while, a solid precipitates out. Therefore, the solid was collected by filtration, and the cake was dried under reduced pressure at 60 ° C. to obtain 1.7 g of the desired product (60% yield).
【0029】合成例2(例示化合物15の合成) アデニン1.35g、エチルイソチオシアナート1.7
4gをジメチルホルムアミド50ml中、90〜95℃
で20時間加熱する。更に120〜125℃で20時間
反応させた。冷却後、反応液に水100mlを加え1週
間放置したところ、針状結晶が析出した。結晶を濾取、
水洗後、60℃で減圧乾燥し、目的物0.50g(22
%収率)を得た。Synthesis Example 2 (Synthesis of Exemplified Compound 15) 1.35 g of adenine, 1.7 of ethyl isothiocyanate
4 g in 90 ml of dimethylformamide at 90-95 ° C
For 20 hours. Further, the reaction was carried out at 120 to 125 ° C. for 20 hours. After cooling, 100 ml of water was added to the reaction solution, and the mixture was allowed to stand for 1 week, whereupon needle-like crystals were precipitated. Filter the crystals,
After washing with water, the precipitate was dried under reduced pressure at 60 ° C.
% Yield).
【0030】本発明のその他の硫黄化合物も同様の方法
で合成することができる。The other sulfur compounds of the present invention can be synthesized in a similar manner.
【0031】本発明の硫黄化合物に加えて、水溶性金化
合物をハロゲン化銀1モル当たり1×10-9〜1×10
-4モル併用することにより、一層の高感度・低カブリが
達成される。In addition to the sulfur compound of the present invention, a water-soluble gold compound is used in an amount of 1 × 10 -9 to 1 × 10 9 per mol of silver halide.
By using -4 moles together, higher sensitivity and lower fog can be achieved.
【0032】有用な水溶性金化合物としては、例えば米
国特許2,399,083号及び同2,642,361
号に記載されるような塩化金酸、カリウムオーレート、
カリウムオーリシアニド、カリウムオーリチオシアナー
ト、金スルフィド、カリウムクロロオーレート、金セレ
ニド等、並びに下記の如き化合物が挙げられる。Useful water-soluble gold compounds include, for example, US Pat. Nos. 2,399,083 and 2,642,361.
Chloroauric acid, potassium aurate, as described in
Examples include potassium auricyanide, potassium aurithiocyanate, gold sulfide, potassium chloroaurate, gold selenide and the like, and the following compounds.
【0033】[0033]
【化8】 Embedded image
【0034】本発明の硫黄化合物は、水又はメタノー
ル、エタノール、弗素化アルコール、フェノキシエタノ
ール等の水混和性の有機溶媒の単独又は混合溶媒の溶液
としてか、あるいは微結晶分散物として乳剤製造時の任
意の次期に添加するが、化学熟成開始時に添加すること
が好ましい。硫黄化合物の添加量は、乳剤の種類、使用
される条件等によって一様ではないが、通常はハロゲン
化銀1モル当たり3×10-8〜1×10-3モルの範囲に
あり、好ましくは1×10-7〜5×10-4モルである。The sulfur compound of the present invention may be used as a solution of water or a water-miscible organic solvent such as methanol, ethanol, fluorinated alcohol, phenoxyethanol or the like, alone or as a mixed solvent, or as a microcrystalline dispersion during emulsion production. , But is preferably added at the start of chemical ripening. The addition amount of the sulfur compound is not uniform depending on the type of the emulsion, the conditions used, and the like, but is usually in the range of 3 × 10 -8 to 1 × 10 -3 mol per mol of silver halide, and is preferably. It is 1 × 10 −7 to 5 × 10 −4 mol.
【0035】化学熟成時のpAg(銀イオン濃度の逆数
の対数)値としては8.0〜11.0であることが好ま
しい。The pAg (logarithm of the reciprocal of silver ion concentration) during chemical ripening is preferably 8.0 to 11.0.
【0036】化学熟成時には、他の化学増感剤を併用す
ることもできる。併用できる化学増感剤としては、例え
ば米国特許2,419,973号、同2,487,85
0号、同2,518,698号、同2,521,925
号、同2,521,926号、同2,694,637
号、同2,983,610号等に記載されるアミン化合
物誘導体や塩化第一錫等の還元性物質、米国特許2,4
48,060号、同2,566,245号、同2,56
6,263号等に記載されている白金、パラジウム、ロ
ジウムの様な貴金属の塩等を挙げることができる。At the time of chemical ripening, other chemical sensitizers can be used in combination. Examples of chemical sensitizers that can be used in combination include, for example, U.S. Pat. Nos. 2,419,973 and 2,487,85.
No. 0, 2,518,698, 2,521,925
Nos. 2,521,926 and 2,694,637
Compounds described in US Pat. Nos. 2,983,610 and the like, and reducing substances such as stannous chloride, US Pat.
48,060, 2,566,245, 2,56
No. 6,263, etc., salts of noble metals such as platinum, palladium and rhodium.
【0037】本発明に用いられるハロゲン化銀乳剤は、
臭化銀、沃臭化銀、塩化銀、塩臭化銀、塩沃臭化銀、あ
るいは沃塩化銀等の任意のハロゲン組成のものでよく、
ピー・グラフキデス著のシミー・エ・フィジック・フォ
トグラフィック(PaulMontel社刊,1967
年)、ジー・エフ・デュフィン著のフォトグラフィック
・エマルジョン・ケミストリー(The Focal
Press社刊,1966年)、ヴイ・エル・ジェリク
マン等共著のメイキング・アンド・コーティング・フォ
トグラフィック・エマルジョン(The Focal
Press社刊,1964年)等に記載された方法、特
開昭51−39027号、同55−142329号、同
58−113928号、同54−48521号及び同5
8−49938号、同60−138538号等、日本写
真学会昭和58年年次大会要旨集88頁の方法によって
調製できる。即ち、酸性法、中性法、アンモニア法等の
何れでもよく、又、可溶性銀塩と可溶性ハロゲン塩を反
応させる形式としては、片側混合法、同時混合法、それ
らの組合せ、あるいは粒子を銀イオン過剰の下に形成さ
せる方法(逆混合法)、微細な種結晶に可溶性銀塩と可
溶性ハロゲン塩を供給して成長させる方法等の何れを用
いてもよい。The silver halide emulsion used in the present invention is:
Any halogen composition such as silver bromide, silver iodobromide, silver chloride, silver chlorobromide, silver chloroiodobromide, or silver iodochloride may be used.
Simmy & Physic Photographics by P. Grafkides (PaulMontel, 1967)
Year), Photographic Emulsion Chemistry by GF Duffin (The Focal)
Press, 1966), Making and Coating Photographic Emulsion (The Focal) co-authored by V. El Jerikmmann and others.
Press, 1964), JP-A-51-39027, JP-A-55-142329, JP-A-58-113928, JP-A-54-48521, and JP-A-5-48521.
No. 8-49938, No. 60-138538, etc., and can be prepared by the method described in the Abstracts of the 58th Annual Meeting of the Photographic Society of Japan, 1983, page 88. That is, any of an acidic method, a neutral method, an ammonia method and the like may be used, and a method of reacting a soluble silver salt and a soluble halide salt includes a one-sided mixing method, a double-mixing method, a combination thereof, or a method in which grains are mixed with silver ions. Either a method of forming under excess (reverse mixing method), a method of supplying a soluble silver salt and a soluble halogen salt to a fine seed crystal and growing the seed crystal may be used.
【0038】乳剤のハロゲン化銀粒子サイズ分布は狭く
とも広くとも何れでもよいが、粒子サイズの揃った、い
わゆる単分散性であることが好ましい。具体的には、 (粒径の標準偏差/平均粒径)×100=粒径分布の広
さ(%) によって表せる相対標準偏差(変動係数)で分布の広さ
を定義した時、25%以下のものが好ましく、更に好ま
しくは20%以下、特に好ましくは15%以下である。The silver halide grain size distribution of the emulsion may be either narrow or wide, but is preferably monodisperse with uniform grain sizes. Specifically, when the width of the distribution is defined by the relative standard deviation (coefficient of variation) expressed by (standard deviation of particle size / average particle size) × 100 = width (%) of particle size distribution, 25% or less Is preferred, more preferably 20% or less, particularly preferably 15% or less.
【0039】用いられるハロゲン化銀粒子の平均粒径は
特に限定されないが、0.05〜2.0μm、好ましく
は、0.1〜1.2μmである。The average grain size of the silver halide grains to be used is not particularly limited, but is 0.05 to 2.0 μm, preferably 0.1 to 1.2 μm.
【0040】乳剤中に含まれるハロゲン化銀粒子は立方
体、8面体、14面体の様な規則的な形状でもよく、平
板状となる双晶の様な不規則な形状でもよく、又、両者
の混合でもよい。ハロゲン化銀粒子を混合使用する際の
混合比は、発明の効果が失われない範囲であれば任意の
比率で混合できるが、具体的には銀重量で90:10〜
10:90が好ましく、より好ましくは75:25〜2
5:75である。The silver halide grains contained in the emulsion may have a regular shape such as a cubic, octahedral or tetradecahedral shape, an irregular shape such as a flat twin, or both. It may be mixed. The mixing ratio at the time of mixing and using the silver halide grains may be any ratio as long as the effects of the invention are not lost.
10:90 is preferred, and more preferably 75: 25-2.
5:75.
【0041】双晶とは、一つの粒子内に一つ以上の双晶
面を有するハロゲン化銀結晶であるが、双晶の形態の分
類はクラインとモイザーによる報文フォトグラフィッシ
ェ・コレスポンデンツ(Photographishe
Korrespondenz)99巻,99頁、同1
00巻,57頁に詳しく述べられている。Twins are silver halide crystals having one or more twin planes in one grain, and the twins are classified according to the report by Klein and Moiser. (Photographhishhe
Korespondenz) Vol. 99, p. 99, ibid.
00, p. 57.
【0042】本発明に用いられる双晶粒子は、主として
偶数枚の平行な双晶面を有するものであり、これらの双
晶面は互いに平行であっても平行でなくてもよいが、特
に好ましくは2枚の双晶面を有するものである。The twin grains used in the present invention mainly have an even number of parallel twin planes. These twin planes may or may not be parallel to each other, but are particularly preferred. Has two twin planes.
【0043】平板状ハロゲン化銀粒子は、粒子直径/厚
さ(アスペクト比)の比の平均値(平均アスペクト比)
が2以上であり、平均アスペクト比としては2〜10が
好ましく、更に好ましくは3〜8である。これら平板状
ハロゲン化銀粒子は、結晶の外壁は実質的に殆どが(1
11)面から成るもの、あるいは(100)面から成る
ものであってもよい。又、(111)面と(100)面
とを併せ持つものであってもよい。この場合には、粒子
表面の50%以上が(111)面であり、より好ましく
は60〜90%が(111)面であり、特に好ましくは
70〜95%が(111)面である。(111)面以外
の面は主として(100)面であることが好ましい。こ
の面比率は、増感色素の吸着における(111)面と
(100)面との吸着依存性の違いを利用した「T.T
ani;J.Imaging Sci.,29,165
(1985)」により求めることができる。The average value (average aspect ratio) of the ratio of grain diameter / thickness (aspect ratio) is used for tabular silver halide grains.
Is 2 or more, and the average aspect ratio is preferably 2 to 10, more preferably 3 to 8. In these tabular silver halide grains, the outer wall of the crystal is substantially almost (1).
It may be composed of 11) plane or composed of (100) plane. Further, it may have both the (111) plane and the (100) plane. In this case, 50% or more of the particle surface is the (111) plane, more preferably 60 to 90% is the (111) plane, and particularly preferably 70 to 95% is the (111) plane. It is preferable that the plane other than the (111) plane is mainly the (100) plane. This plane ratio is determined by utilizing the difference in the dependence of the adsorption of the sensitizing dye between the (111) plane and the (100) plane on the adsorption of the sensitizing dye.
ani; Imaging Sci. , 29,165
(1985) ".
【0044】平板状ハロゲン化銀粒子は厚さの分布が小
さいことが好ましい。具体的には、 (厚さの標準偏差/平均厚さ)×100=厚さ分布の広
さ(%) によって分布の広さを定義した時、25%以下のものが
好ましく、更に好ましくは20%以下、特に好ましくは
15%以下である。Tabular silver halide grains preferably have a small thickness distribution. Specifically, when the width of the distribution is defined by (standard deviation of thickness / average thickness) × 100 = width (%) of thickness distribution, it is preferably 25% or less, more preferably 20% or less. %, Particularly preferably 15% or less.
【0045】更に、平板状ハロゲン化銀粒子乳剤中の個
々の粒子のハロゲン含量率の分布も小さいことが好まし
い。具体的には、 (ハロゲン含有率の標準偏差/平均ハロゲン含有率)×
100 =ハロゲン含有率の広さ(%) によって分布の広さを定義した時、25%以下のものが
好ましく、更に好ましくは20%以下、特に好ましくは
15%以下である。Further, the distribution of the halogen content of each grain in the tabular silver halide grain emulsion is preferably small. Specifically, (standard deviation of halogen content / average halogen content) ×
When the width of the distribution is defined by 100 = the width (%) of the halogen content, the width is preferably 25% or less, more preferably 20% or less, and particularly preferably 15% or less.
【0046】平板状ハロゲン化銀粒子は六角形であるこ
とが好ましい。六角形の平板状粒子(以下、六角平板粒
子と称す場合もある)とは、その主平面{(111)
面}の形状が六角形であり、その最大隣接比率が1.0
〜2.0であることを言う。ここで最大隣接辺比率と
は、六角形を形成する最小の長さを有する辺の長さに対
する最大の長さを有する辺の長さの比である。六角平板
粒子は最大隣接辺比率が1.0〜2.0であれば、その
角が丸みを帯びていることも好ましく、更に角がとれ、
略、円形の平板粒子となっていることも好ましい。角が
丸味を帯びている場合の辺の長さは、その辺の直線部分
を延長し、隣接する辺の直線部分を延長した線との交点
との間の距離で表される。The tabular silver halide grains are preferably hexagonal. Hexagonal tabular grains (hereinafter sometimes referred to as hexagonal tabular grains) refer to the main plane {(111)
The shape of the surface} is hexagonal and the maximum adjacent ratio is 1.0
~ 2.0. Here, the maximum adjacent side ratio is a ratio of the length of the side having the maximum length to the length of the side having the minimum length forming the hexagon. If the hexagonal tabular grains have a maximum adjacent side ratio of 1.0 to 2.0, it is preferable that the corners are rounded, and the corners are further removed.
It is also preferred that the tabular grains are substantially circular. The length of a side having a rounded corner is represented by the distance between the intersection of the straight line portion of the side and the line extending from the straight line of the adjacent side.
【0047】六角平板粒子の六角形を形成する各辺は、
その1/2以上が実質的に直線からなることが好まし
く、隣接辺比率が1.0〜1.5であることがより好ま
しい。Each side forming the hexagon of the hexagonal tabular grain is:
It is preferable that at least half thereof be substantially a straight line, and it is more preferable that the adjacent side ratio be 1.0 to 1.5.
【0048】ハロゲン化粒子の転位は、例えばJ.F.
Hamilton;Phot.Sci.Eng.,57
(1967)や、T.Shiozawa;J.Soc.
Phot.Sci.Japan,35,213(197
2)に記載の、低温での透過型電子顕微鏡を用いた直接
的な方法により観察することができる。即ち、乳剤から
粒子に転位が発生する程の圧力を掛けないよう注意して
取り出したハロゲン化銀粒子を電子顕微鏡観察用のメッ
シュに載せ、電子線による損傷(プリントアウト等)を
防ぐように試料を冷却した状態で透過法により観察を行
う。この時、粒子の厚みが厚いほど、電子線が透過し難
くなるので、高圧型(0.25μmの厚さの粒子に対し
て200kV以上)の電子顕微鏡を用いた方がより鮮明
に観察することができる。このような方法により得られ
た粒子の写真より、各粒子についての転位の位置及び数
を求めることができる。The dislocation of halogenated grains is described, for example, in J. Am. F.
Hamilton; Photo. Sci. Eng. , 57
(1967) and T.W. Shiozawa; Soc.
Photo. Sci. Japan, 35, 213 (197)
It can be observed by a direct method using a transmission electron microscope at a low temperature as described in 2). That is, the silver halide grains taken out from the emulsion so as not to apply enough pressure to generate dislocations on the grains are placed on a mesh for electron microscopic observation, and the sample is prepared so as to prevent damage (printout, etc.) by electron beams. Observation is performed by a transmission method in a state of cooling. At this time, the thicker the particle, the more difficult it is for the electron beam to pass through. Therefore, it is better to use a high-pressure electron microscope (200 kV or more for a particle having a thickness of 0.25 μm) to observe more clearly. Can be. From the photographs of the particles obtained by such a method, the position and number of dislocations for each particle can be determined.
【0049】転位の位置は、ハロゲン化粒子の中心から
外表面に向けて0.58L〜1.0Lまでの領域に発生
していることが望ましいが、より好ましくは0.80L
〜0.98Lの領域に発生しているものである。転位線
の方向は、おおよそ中心から外表面に向かう方向である
が、しばしば蛇行している。ハロゲン化銀粒子の中心と
は、日本写真学会講演要集,46〜48頁に掲載の井上
等の要旨に示す方法と同様に、ハロゲン化銀微結晶をメ
タクリル樹脂中に分散して固化し、ミクロトームにて超
薄切片とし、断面積が最大となったもの及びそれより9
0%以上の断面積を有する切片試料に着目し、断面に対
して最小となる外接円を描いた時の円の中心である。It is desirable that the dislocation position is generated in a region from 0.58 L to 1.0 L from the center of the halogenated grain toward the outer surface, but more preferably 0.80 L
It occurs in the region of .about.0.98 L. The direction of the dislocation line is approximately from the center to the outer surface, but often meanders. The center of the silver halide grains is defined by dispersing silver halide microcrystals in methacrylic resin and solidifying the same as in the method described in the abstract of Inoue et al. Ultrathin sections with a microtome, with the largest cross-sectional area and 9
Focusing on a section sample having a cross-sectional area of 0% or more, this is the center of a circle when a circumscribed circle that is the minimum with respect to the cross section is drawn.
【0050】本発明において中心から外表面までの距離
Lは、前記円の中心から外に向けて直線を引いた時、粒
子の外周と交わる点と円の中心との距離と定義する。In the present invention, the distance L from the center to the outer surface is defined as the distance between the point of intersection of the outer periphery of the particle and the center of the circle when a straight line is drawn outward from the center of the circle.
【0051】転位の数については、1本以上の転位を含
む粒子が50%(個数)以上存在することが望ましく、
転位線を有する平板粒子数の比率(数)が高いほど好ま
しい。Regarding the number of dislocations, it is preferable that 50% (number) of particles containing one or more dislocations exist.
The higher the ratio (number) of the number of tabular grains having dislocation lines, the better.
【0052】平板状粒子において粒径とは、粒子の投影
像を同面積の円像に換算した時の直径である。粒子の投
影面積は、この粒子面積の和から求めることができる。
即ち、何れも粒子の重なりが生じない程度に試料台上に
分布されたハロゲン化銀結晶サンプルを、電子顕微鏡観
察することによって得ることができる。In the tabular grains, the particle diameter is a diameter when a projected image of the grains is converted into a circular image having the same area. The projected area of a particle can be determined from the sum of the particle areas.
That is, a silver halide crystal sample distributed on a sample table to such an extent that no grains are overlapped can be obtained by observing the sample with an electron microscope.
【0053】粒子の平均投影面積径は、該粒子の投影面
積の円相当直径で表し、好ましくは0.30μm以上で
あるが、より好ましくは0.30〜5μm、更に好まし
くは0.40〜2μmである。粒径は、該粒子を電子顕
微鏡で1万〜7万倍に拡大投影して、そのプリント上の
投影時の面積を実測することによって得ることができ
る。又、平均粒径φiは、測定粒径個数をnとし、粒径
diを有する粒子頻度をniとした時に、次式から求める
ことができる。The average projected area diameter of a grain is represented by a circle equivalent diameter of the projected area of the grain, and is preferably 0.30 μm or more, more preferably 0.30 to 5 μm, and still more preferably 0.40 to 2 μm. It is. The particle size can be obtained by projecting the particles at a magnification of 10,000 to 70,000 times with an electron microscope and actually measuring the projected area on the print. The average particle diameter phi i is the measured particle径個number is n, the particles often having a particle size d i is taken as n i, can be calculated from the following equation.
【0054】平均粒径(φi)=(Σnidi)/n (測定粒子個数は無差別に1,000個以上であるとす
る) 粒子の厚さは、電子顕微鏡によって試料を斜めから観察
することによって得ることができる。本発明の平板状粒
子の好ましい厚みは0.03〜1.0μmであり、より
好ましくは0.05〜0.5μmである。[0054] Mean particle diameter (φ i) = (Σn i d i) / n ( number of measured grains and is indiscriminately more than 1,000) of the grain thickness, a sample from an oblique by electron microscopy Obtained by observation. The preferred thickness of the tabular grains of the invention is from 0.03 to 1.0 μm, more preferably from 0.05 to 0.5 μm.
【0055】ハロゲン化銀粒子が有する平行な2以上の
双晶面間の最も長い距離(a)と粒子の厚み(b)の比
(b/a=アスペクト比)が5以上であることが好まし
く、このような粒子の存在数の比率が50%以上である
ことが好ましい。The ratio (b / a = aspect ratio) of the longest distance (a) between two or more parallel twin planes of the silver halide grains and the thickness (b) of the grains is preferably 5 or more. The ratio of the number of such particles is preferably 50% or more.
【0056】双晶面間距離(a)は以下のように求める
ことができる。即ち、上記の透過型電子顕微鏡を用いた
切片の観察を行い、主平面に対しほぼ垂直に切断された
断面を示す平板状ハロゲン化銀粒子を任意に100個以
上選び、それぞれの粒子について(a)を測定し、その
加算平均により求めることができる。(a)の平均値は
0.008μm以上であるのが好ましく、更に好ましく
は0.010〜0.05μmである。又、(a)が上記
値範囲にあると同時に、その変動係数が35%以下であ
ることが必要であるが、好ましくは30%以下である。The distance between twin planes (a) can be determined as follows. That is, the section was observed using the above-mentioned transmission electron microscope, and arbitrarily selected 100 or more tabular silver halide grains exhibiting a cross section cut almost perpendicularly to the main plane. ) Is measured, and the average is obtained. The average value of (a) is preferably 0.008 μm or more, and more preferably 0.010 to 0.05 μm. In addition, it is necessary that (a) is within the above-mentioned value range and the coefficient of variation must be 35% or less, and preferably 30% or less.
【0057】更に、アスペクト比と粒子の厚みの因子を
加味して、次式で表現される平板性:A=ECD/b2
が20以上であることが好ましい。ここでECDは平板
粒子の平均投影直径(μm)を指し、(b)は粒子の厚
みである。又、平均投影直径とは、平板粒子の投影面積
と等しい面積を有する円の直径の数平均を表す。Further, taking into account the factors of the aspect ratio and the grain thickness, tabularity represented by the following equation: A = ECD / b 2
Is preferably 20 or more. Here, ECD indicates the average projected diameter (μm) of tabular grains, and (b) indicates the thickness of the grains. Further, the average projected diameter indicates the number average of the diameter of a circle having an area equal to the projected area of the tabular grains.
【0058】本発明に用いられるハロゲン化銀粒子は、
ハロゲン化銀粒子内に実質的にハロゲン組成の異なる少
なくとも二つの層構造を持つコア/シェル型構造でも、
均一な組成のものでもよいが、コア/シェル型構造を有
することが好ましい。この場合、粒子中心部には、コア
とは異なるハロゲン組成領域を持つことがあり得る。こ
のような場合、種粒子のハロゲン組成は、臭化銀、沃臭
化銀、塩沃臭化銀、塩臭化銀、塩化銀等の任意の組合せ
のものが持てる。The silver halide grains used in the present invention are:
A core / shell type structure having at least two layer structures having substantially different halogen compositions in silver halide grains,
It may have a uniform composition, but preferably has a core / shell structure. In this case, the grain center may have a halogen composition region different from that of the core. In such a case, the halogen composition of the seed grains can be any combination of silver bromide, silver iodobromide, silver chloroiodobromide, silver chlorobromide, silver chloride and the like.
【0059】コア/シェル型構造のハロゲン化銀粒子の
製造方法については、例えば西独特許1,169,29
0号、英国特許1,027,146号、特開昭57−1
5423号、特公昭51−1417号等に記載された方
法を採用することができる。A method for producing silver halide grains having a core / shell type structure is described in, for example, West German Patent 1,169,29.
0, British Patent 1,027,146, JP-A-57-1
No. 5423, Japanese Patent Publication No. 51-1417, etc. can be employed.
【0060】本発明に用いるハロゲン化銀乳剤の平均沃
化銀含有率は6モル%以下が好ましく、より好ましくは
0.1〜1.5モル%である。該ハロゲン組成の異なる
層構造を有する粒子においては、粒子内部に高沃化銀
層、最表面層に低沃化銀層又は臭化銀層を有する粒子が
好ましい。この時、最高の沃化銀含有率を有する内部層
(コア)の沃化銀率は、2.5モル%以上のものが好ま
しく、より好ましくは5モル%以上であり、最表面層
(シェル)の沃化銀含有率は0〜5モル%で、好ましく
は0〜3モル%であり、かつコアの沃化銀含有率がシェ
ルの沃化銀含有率より少なくとも3モル%以上多いこと
が好ましい。コアの沃化銀分布は通常は均一であるが、
分布を持っていてもよい。例えば、中心部から外部に向
かうにつれ、高濃度となっていても、中間領域に極大又
は極小濃度を有していてもよい。The average silver iodide content of the silver halide emulsion used in the present invention is preferably 6 mol% or less, more preferably 0.1 to 1.5 mol%. Of the grains having a layer structure with a different halogen composition, grains having a high silver iodide layer inside the grains and a low silver iodide layer or a silver bromide layer on the outermost layer are preferred. At this time, the silver iodide ratio of the inner layer (core) having the highest silver iodide content is preferably 2.5 mol% or more, more preferably 5 mol% or more. The content of silver iodide is preferably 0 to 5 mol%, more preferably 0 to 3 mol%, and the silver iodide content of the core is at least 3 mol% or more higher than the silver iodide content of the shell. preferable. The silver iodide distribution of the core is usually uniform,
It may have a distribution. For example, as the concentration goes from the center to the outside, the concentration may become higher, or the intermediate region may have a maximum or minimum concentration.
【0061】本発明においては、所謂ハロゲン変換型
(コンバージョン型)の粒子であっても構わない。ハロ
ゲン変換量は銀量に対して0.2〜2.0モル%が好ま
しく、変換の時期は物理熟成中でも物理熟成終了後でも
よい。ハロゲン変換の方法としては、通常、ハロゲン変
換前の粒子表面のハロゲン組成よりも銀との溶解度積の
小さいハロゲン水溶液又はハロゲン化銀微粒子を添加す
る。この時の微粒子サイズとしては0.2μm以下が好
ましく、より好ましくは0.02〜0.1μmである。In the present invention, so-called halogen conversion type (conversion type) particles may be used. The halogen conversion amount is preferably from 0.2 to 2.0 mol% based on the silver amount, and the conversion may be performed during physical ripening or after physical ripening. As a halogen conversion method, usually, an aqueous halogen solution or silver halide fine particles having a solubility product with silver smaller than the halogen composition on the grain surface before the halogen conversion is added. The particle size at this time is preferably 0.2 μm or less, more preferably 0.02 to 0.1 μm.
【0062】ハロゲン化銀粒子の沃化銀含有率及び平均
沃化銀含有率は、EPMA法(Electron Pr
obe Micro Analyzer)を用いること
により求めることが可能である。この方法は、乳剤粒子
を互いに接触しないように良く分散したサンプルを作成
し、電子ビームを照射する電子線励起によるX線分析よ
り極小な部分の元素分析が行える。この方法により、各
粒子から放射される銀及び沃度の特性X線強度を求める
ことにより個々の粒子のハロゲン組成が決定できる。少
なくとも100個の粒子についてEPMA法により沃化
銀含有率を求めれば、それらの平均から平均沃化銀含有
率が求められる。The silver iodide content and the average silver iodide content of silver halide grains were determined by an EPMA method (Electron Pr).
ob Micro Analyzer). According to this method, a sample in which emulsion grains are well dispersed so as not to be in contact with each other is prepared, and element analysis of a portion smaller than X-ray analysis by electron beam excitation for irradiating an electron beam can be performed. By this method, the halogen composition of each grain can be determined by determining the characteristic X-ray intensity of silver and iodine emitted from each grain. If the silver iodide content is determined for at least 100 grains by the EPMA method, the average silver iodide content can be determined from the average thereof.
【0063】更に、ハロゲン化銀粒子は、粒子を形成す
る過程及び/又は成長する過程で、カドミウム塩、亜鉛
塩、鉛塩、タリウム塩、イリジウム塩(錯塩を含む)、
ロジウム塩(錯塩を含む)及び鉄塩(錯塩を含む)から
選ばれる少なくとも1種の金属イオンを添加し、粒子内
部に及び/又は粒子表面層にこれらの金属元素を含有さ
せることができ、又、適当な還元的雰囲気に置くことに
より、粒子内部及び/又は粒子表面に還元増感核を付与
できる。Further, during the process of forming and / or growing the silver halide grains, cadmium salts, zinc salts, lead salts, thallium salts, iridium salts (including complex salts),
At least one metal ion selected from a rhodium salt (including a complex salt) and an iron salt (including a complex salt) can be added, and these metal elements can be contained inside the particles and / or in the particle surface layer. By placing in a suitable reducing atmosphere, a reduction sensitizing nucleus can be provided inside the grains and / or on the surface of the grains.
【0064】又、粒子形成の所望の時点で添加した還元
剤の作用を過酸化水素(水)及びその付加物、ペルオキ
ソ酸塩、オゾン、I2等の酸化剤を所望の時点で添加す
ることによって失活させ、還元剤を抑制又は停止するこ
とが好ましい。酸化剤の添加時期は、ハロゲン化銀粒子
形成時から化学増感工程の金増感剤(金増感剤を用いな
い場合には、化学増感剤)添加前までならば任意であ
る。The effect of the reducing agent added at a desired point in time of particle formation can be improved by adding an oxidizing agent such as hydrogen peroxide (water) and its adduct, peroxoacid salt, ozone, and I2 at a desired point in time. It is preferable to deactivate and suppress or stop the reducing agent. The oxidizing agent may be added at any time from when the silver halide grains are formed to before the addition of a gold sensitizer (or a chemical sensitizer if no gold sensitizer is used) in the chemical sensitization step.
【0065】ハロゲン化銀写真乳剤は、ハロゲン化銀粒
子の成長の終了時に不要な可溶性塩類を除去してもよい
し、あるいは含有させたままでもよい。該塩類を除去す
る場合には、リサーチ・ディスクロージャ(Resea
rch Disclosure、以下RDと略す)N
o.17643号II項に記載の方法に基づいて行うこと
ができる。In the silver halide photographic emulsion, unnecessary soluble salts may be removed at the end of the growth of the silver halide grains, or may be kept contained. When removing the salts, use a Research Disclosure (Resea).
rch Disclosure (hereinafter abbreviated as RD) N
o. It can be performed based on the method described in 17643 No. II.
【0066】本発明においては、各々別個に形成した2
種以上のハロゲン化銀乳剤を任意に混合して用いること
ができる。In the present invention, each of the 2
More than one kind of silver halide emulsion can be arbitrarily mixed and used.
【0067】感光材料を作製するために用いられる親水
性保護コロイドには、プロダクト・ライセシング・イン
デックス,92巻,108頁の「Vehicles」の
項に記載されるような、通常の乳剤に用いられるゼラチ
ンの他に、アセチル化ゼラチンやフタル化ゼラチン等の
ゼラチン誘導体、水溶性セルロース誘導体その他の合成
又は天然の親水性ポリマーが含まれる。The hydrophilic protective colloid used for preparing the light-sensitive material includes gelatin used in ordinary emulsions as described in "Products Index", Vol. 92, p. 108, "Vehicles". In addition, gelatin derivatives such as acetylated gelatin and phthalated gelatin, water-soluble cellulose derivatives, and other synthetic or natural hydrophilic polymers are included.
【0068】感光材料には、必要に応じて当業界公知の
各種技術、添加剤を用いることができる。例えば、感光
性乳剤層に加えて、保護層、フィルター層、ハレーショ
ン防止層、クロスオーバー光カット層、バッキング層等
の補助層を設けることができ、これらの層中には、各種
の化学増感剤、貴金属増感剤、感光色素、強色増感剤、
カプラー、高沸点溶剤、カブリ防止剤、安定剤、現像抑
制剤、漂白促進剤、定着促進剤、混色防止剤、ホルマリ
ンスカベンジャー、色調剤、硬膜剤、界面活性剤、増粘
剤、可塑剤、滑り剤、紫外線吸収剤、イラジエーション
防止染料、フィルター光吸収染料、防黴剤、ポリマーラ
テックス、重金属、帯電防止剤、マット剤等を各種の方
法で含有させることができる。For the photographic material, various techniques and additives known in the art can be used as necessary. For example, in addition to the photosensitive emulsion layer, auxiliary layers such as a protective layer, a filter layer, an antihalation layer, a crossover light-cutting layer, and a backing layer can be provided. Agents, noble metal sensitizers, photosensitive dyes, supersensitizers,
Couplers, high boiling solvents, antifoggants, stabilizers, development inhibitors, bleach accelerators, fixing accelerators, color mixture inhibitors, formalin scavengers, color toning agents, hardeners, surfactants, thickeners, plasticizers, A slipping agent, an ultraviolet absorber, an anti-irradiation dye, a filter light-absorbing dye, a fungicide, a polymer latex, a heavy metal, an antistatic agent, a matting agent and the like can be contained by various methods.
【0069】上述したこれらの添加剤は、より詳しくは
前記RD17643(1978年12月),23頁III
項〜29頁XXI項、RD18431(1979年8
月)、RD18716(1979年11月),648〜
651頁及びRD308119(1989年12月),
996頁III−A項〜1012頁XXI−E項に記載され
る。The above-mentioned additives are described in more detail in RD17643 (December 1978), p.
Pp. 29-XXI, RD 18431 (August 1979
Mon), RD18716 (November 1979), 648-
651 and RD308119 (December 1989),
It is described in page 996, paragraphs III-A to 1012, paragraphs XXI-E.
【0070】感光材料に用いることのできる支持体とし
ては、例えば前述のRD17643,28頁及びRD3
08119,1009頁やプロダクト・ライセシング・
インデックス,92巻,108頁の「Support
s」の項に記載されるものが挙げられる。Examples of the support which can be used for the light-sensitive material include the aforementioned RD17643, page 28 and RD3
08119, 1009 pages and Product Licensing
Index, Vol. 92, p. 108, “Support
s ".
【0071】適当な支持体としては、三酢酸セルロー
ス、硝酸セルロース、ポリエチレンテレフタレート、ポ
リエチレン−2,6−ナフタレートのようなポリエステ
ル、ポリエチレンのようなポリオレフィン、ポリスチレ
ン、バライタ紙、ポリエチレン等をラミネートした紙、
ガラス、金属等を挙げることができる。これら支持体の
表面は、塗布層の接着を良くするために、例えばコロナ
放電処理、紫外線照射や下引きポリマー接着層の設置等
の下地加工が施される。Suitable supports include cellulose triacetate, cellulose nitrate, polyesters such as polyethylene terephthalate and polyethylene-2,6-naphthalate, polyolefins such as polyethylene, polystyrene, baryta paper, paper laminated with polyethylene, etc.
Glass, metal and the like can be mentioned. In order to improve the adhesion of the coating layer, the surfaces of these supports are subjected to a base treatment such as a corona discharge treatment, an ultraviolet irradiation, and the setting of a subbing polymer adhesive layer.
【0072】前述のハロゲン化銀乳剤を含有した本発明
の感光材料は、例えば黒白感光材料(医療用感材、印刷
用感材、マイクロフィルム感材、一般撮影用ネガ感材
等)、カラー感光材料(カラーネガ感材、カラーリバー
サル感材、カラープリント用感材等)、拡散転写用感光
材料、熱現像感光材料等に適用できる。Examples of the light-sensitive material of the present invention containing the above-mentioned silver halide emulsion include black-and-white light-sensitive materials (medical light-sensitive material, printing light-sensitive material, microfilm light-sensitive material, negative film light-sensitive material for general photography, etc.), color light-sensitive materials and the like. It can be applied to materials (color negative sensitive material, color reversal sensitive material, color print sensitive material, etc.), photosensitive material for diffusion transfer, photothermographic material and the like.
【0073】本発明の感光材料を現像処理するには、例
えばプロダクト・ライセシング・インデックス,92巻,
110頁の「Process」の項、T.H.ジェーム
ス著のザ・セオリィ・オブ・ザ・フォトグラフィック・
プロセス第4版(The Theory of the
Photographic Process,fou
rth Edition)291〜334頁及びジャー
ナル・オブ・ザ・アメリカン・ケミカル・ソサエティ
(J.Am.Chem.Soc.)73巻,3100頁
(1951)に記載された如き現像剤が有効に使用し得
る。For developing the light-sensitive material of the present invention, for example, the Product Licensing Index, Vol.
See “Process” on page 110; H. The Theory of the Photographic by James
Process 4th edition (The Theory of the
Photographic Process, fou
rth Edition) pp. 291-334 and Journal of the American Chemical Society (J. Am. Chem. Soc.) 73, 3100 (1951). .
【0074】[0074]
【実施例】以下に本発明の具体的実施例を述べるが、本
発明の実施の態様はこれに限定されるものではない。EXAMPLES Specific examples of the present invention will be described below, but the embodiments of the present invention are not limited to these examples.
【0075】実施例1 〈種乳剤−Iの調製〉下記のようにして種乳剤−Iを調
製した。Example 1 <Preparation of seed emulsion-I> Seed emulsion-I was prepared as follows.
【0076】 A1 オセインゼラチン 24.2g 水 9657ml 界面活性剤SA−1の10%エタノール水溶液 6.78ml 臭化カリウム 10.8g 10%硝酸 114ml B1 2.5N硝酸銀水溶液 2825ml C1 臭化カリウム 824g 沃化カリウム 23.5g 水で 2825mlに仕上げる D1 1.75N臭化カリウム水溶液 下記銀電位制御量 SA−1:ポリプロピレンオキシ−ポリエチレンオキシ−ジサクシネートナトリ ウム塩 35℃で特公昭58−58288号、同58−5828
9号記載の混合撹拌機を用い、溶液A1に溶液B1及び
溶液C1の各々464.3mlを同時混合法により1.
5分を要して添加し、核形成を行った。A1 ossein gelatin 24.2 g water 9657 ml 10% ethanol solution of surfactant SA-1 6.78 ml potassium bromide 10.8 g 10% nitric acid 114 ml B1 2.5N silver nitrate aqueous solution 2825 ml C1 potassium bromide 824 g iodide Potassium 23.5 g Finished to 2825 ml with water D1 1.75 N aqueous potassium bromide solution Silver potential control amount below SA-1: Polypropyleneoxy-polyethyleneoxy-disuccinate sodium salt JP-B-58-58288, 58 at 35 ° C -5828
Using the mixing stirrer described in No. 9, 464.3 ml of each of the solution B1 and the solution C1 was added to the solution A1 by the simultaneous mixing method.
Nucleation was carried out by adding over 5 minutes.
【0077】溶液B1及び溶液C1の添加を停止した
後、60分の時間を要して溶液A1の温度を60℃に上
昇させ、3%水酸化カリウム水溶液でpHを5.0に合
わせ、再び、溶液B1と溶液C1を同時混合法により、
各々55.4ml/分の流量で42分間添加した。この
35℃から60℃への昇温及び溶液B1、C1による再
同時混合の間の銀電位(飽和銀−塩化銀電極を比較電極
として銀イオン選択電極で測定)を溶液D1を用いて、
それぞれ+8mV及び+16mVになるよう制御した。After stopping the addition of the solution B1 and the solution C1, it takes 60 minutes to raise the temperature of the solution A1 to 60 ° C., adjust the pH to 5.0 with a 3% aqueous solution of potassium hydroxide, and again. , Solution B1 and solution C1 by a simultaneous mixing method,
Each was added at a flow rate of 55.4 ml / min for 42 minutes. The silver potential (measured with a silver ion selective electrode using a saturated silver-silver chloride electrode as a reference electrode) during the temperature rise from 35 ° C to 60 ° C and re-simultaneous mixing with the solutions B1 and C1 was measured using the solution D1.
Control was performed so as to be +8 mV and +16 mV, respectively.
【0078】添加終了後、3%水酸化カリウム水溶液に
よってpHを6に合わせ、直ちに脱塩、水洗を行った。
この種乳剤は、ハロゲン化銀粒子の全投影面積の90%
以上が最大隣接辺比が1.0〜2.0の六角平板粒子よ
り成り、六角平板粒子の平均厚さは0.06μm、平均
粒径(円直径換算)は0.59μmであることを電子顕
微鏡にて確認した。又、厚さの変動係数は40%、双晶
面間距離の変動係数は42%であった。After the addition was completed, the pH was adjusted to 6 with a 3% aqueous potassium hydroxide solution, and immediately desalting and washing were performed.
This seed emulsion accounts for 90% of the total projected area of silver halide grains.
The above description shows that hexagonal tabular grains having a maximum adjacent side ratio of 1.0 to 2.0 were formed, and the average thickness of the hexagonal tabular grains was 0.06 μm and the average grain size (circular diameter conversion) was 0.59 μm. It was confirmed with a microscope. The variation coefficient of the thickness was 40%, and the variation coefficient of the distance between twin planes was 42%.
【0079】〈Em−1の調製〉上記の種乳剤−Iと以
下に示す4種の溶液を用い、コア/シェル型構造を有す
る平板状乳剤を調製した。<Preparation of Em-1> A tabular emulsion having a core / shell structure was prepared using the above seed emulsion-I and the following four kinds of solutions.
【0080】 A2 オセインゼラチン 11.7g 界面活性剤SA−1の10%エタノール水溶液 1.4ml 種乳剤−I 0.10 モル相当 水で 550mlに仕上げる B2 オセインゼラチン 5.9g 臭化カリウム 6.2g 沃化カリウム 0.8g 水で 145mlに仕上げる C2 硝酸銀 10.1g 水で 145mlに仕上げる D2 オセインゼラチン 6.1g 臭化カリウム 94g 水で 304mlに仕上げる E2 硝酸銀 137g 水で 304mlに仕上げる 67℃で激しく撹拌したA2液に、ダブルジェット法に
てB2液とC2液を58分で添加した。次に、同じ液中
にD2液とE2液をダブルジェット法にて48分添加し
た。この間、pHは5.8、pAgは8.7に保った。A2 ossein gelatin 11.7 g 10% aqueous solution of surfactant SA-1 in ethanol 1.4 ml seed emulsion-I 0.10 mol equivalent Equivalent to 550 ml with water B2 ossein gelatin 5.9 g potassium bromide 6. 2g Potassium iodide 0.8g Finish to 145ml with water C2 Silver nitrate 10.1g Finish to 145ml with water D2 Ossein gelatin 6.1g Potassium bromide 94g Finish to 304ml with water E2 Silver nitrate 137g Finish to 304ml with water Vigorous at 67 ° C The solution B2 and the solution C2 were added to the stirred solution A2 by a double jet method in 58 minutes. Next, D2 solution and E2 solution were added to the same solution by a double jet method for 48 minutes. During this time, the pH was kept at 5.8 and the pAg was kept at 8.7.
【0081】添加終了後、種乳剤−Iと同様に脱塩、沈
澱を行い、40℃にてpAg8.5、pH5.85の平
均沃化銀含有率が約0.5モル%の乳剤を得た。After completion of the addition, desalting and precipitation were carried out in the same manner as for seed emulsion-I to obtain an emulsion having a pAg of 8.5 and a pH of 5.85 at 40 ° C. and having an average silver iodide content of about 0.5 mol%. Was.
【0082】得られた乳剤を電子顕微鏡にて観察したと
ころ、投影面積の81%が平均粒径0.96μm、粒径
分布の広さ19%、平均アスペクト比4.5の平板状ハ
ロゲン化銀粒子であった。又、双晶面間距離(a)の平
均は0.019μmであり、(a)の変動係数は28%
であった。When the obtained emulsion was observed with an electron microscope, 81% of the projected area was tabular silver halide having an average grain size of 0.96 μm, a grain size distribution of 19%, and an average aspect ratio of 4.5. Particles. The average of the twin plane distance (a) was 0.019 μm, and the variation coefficient of (a) was 28%.
Met.
【0083】〈Em−2及びEm−3の調製〉種乳剤−
Iの調製における溶液A1中の臭化カリウム量、溶液B
1、C1の添加時間、添加温度、Em−1の調製におけ
る溶液A2中の種乳剤−I、溶液B2中の臭化カリウム
及び沃化カリウム量、添加時のpAg、添加速度、添加
時間、添加温度等を変更する以外はEm−1と同様にし
て平均沃度含有率が、それぞれ1.5モル%、2.5モ
ル%であるコア・シェル型乳剤(コア部の方がシェル部
より沃度含有率が高い)Em−2及びEm−3を調製し
た。<Preparation of Em-2 and Em-3> Seed emulsion
Amount of potassium bromide in solution A1 in preparation of I, solution B
1. Addition time of C1, addition temperature, seed emulsion-I in solution A2 in preparation of Em-1, amount of potassium bromide and potassium iodide in solution B2, pAg at the time of addition, addition speed, addition time, addition A core-shell type emulsion having an average iodine content of 1.5 mol% and 2.5 mol%, respectively, in the same manner as Em-1 except that the temperature and the like are changed (the core portion is higher in iodine content than the shell portion). Em-2 and Em-3 (having a high degree of content) were prepared.
【0084】何れの乳剤も平均アスペクト比が約4.5
の平板状粒子であり、その他の形状的特性は、平均粒径
が、それぞれ1.02μm、0.98μmであり、粒径
の分散係数は21%、22%、平均双晶面間距離(a)
は0.24μm、0.018μm、(a)の変動係数は
30%、33%であった。Each of the emulsions had an average aspect ratio of about 4.5.
Are tabular grains having the following average characteristics: average particle diameters are 1.02 μm and 0.98 μm, respectively; the dispersion coefficient of the particle diameters is 21% and 22%; and the average twin plane distance (a )
Was 0.24 μm, 0.018 μm, and the variation coefficients of (a) were 30% and 33%.
【0085】〈種乳剤−IIの調製〉下記のようにして種
乳剤−IIを調製した。<Preparation of Seed Emulsion-II> Seed Emulsion-II was prepared as follows.
【0086】 A3 オセインゼラチン 24.2g 水 9657ml 界面活性剤SA−1の10%エタノール水溶液 6.78ml 臭化カリウム 10.8g 10%硝酸 114ml B3 2.5N硝酸銀水溶液 2825ml C3 臭化カリウム 841g 水で 2825mlに仕上げる D3 1.75N臭化カリウム水溶液 下記銀電位制御量 42℃で特公昭58−58288号、同58−5828
9号に示される混合撹拌機を用い、溶液A3に溶液B3
及び溶液C3の各々464.3mlを同時混合法により
1.5分を要して添加し、核形成を行った。A3 ossein gelatin 24.2 g water 9657 ml 10% ethanol solution of surfactant SA-1 6.78 ml potassium bromide 10.8 g 10% nitric acid 114 ml B3 2.5N silver nitrate aqueous solution 2825 ml C3 potassium bromide 841 g with water D3 1.75N aqueous solution of potassium bromide D3 1.75N aqueous solution of potassium potential The following silver potential control amount at 42 ° C: JP-B-58-58288, 58-5828
Using a mixing stirrer shown in No. 9
Then, 464.3 ml of each of the solution C3 and the solution C3 were added by a simultaneous mixing method over 1.5 minutes to form nuclei.
【0087】溶液B3及び溶液C3の添加を停止した
後、60分の時間を要して溶液A3の温度を60℃に上
昇させ、3%水酸化カリウム水溶液でpHを5.0に合
わせ、再び溶液B3と溶液C3を同時混合法により、各
々55.4ml/分の流量で42分間添加した。この4
2℃から60℃への昇温及び溶液B3、C3による再同
時混合の間の銀電位(飽和銀−塩化銀電極を比較電極と
して銀イオン選択電極で測定)を、溶液D3を用いて、
それぞれ+8mV及び+16mVになるよう制御した。After the addition of the solution B3 and the solution C3 was stopped, the temperature of the solution A3 was raised to 60 ° C. over a period of 60 minutes, and the pH was adjusted to 5.0 with a 3% aqueous potassium hydroxide solution. The solution B3 and the solution C3 were added at a flow rate of 55.4 ml / min for 42 minutes by the simultaneous mixing method. This 4
The silver potential (measured with a silver ion selective electrode using a saturated silver-silver chloride electrode as a reference electrode) during the temperature rise from 2 ° C. to 60 ° C. and re-mixing with the solutions B3 and C3 was measured using the solution D3.
Control was performed so as to be +8 mV and +16 mV, respectively.
【0088】添加終了後、3%水酸化カリウム水溶液に
よってpHを6に合わせ、直ちに脱塩、水洗を行った。
この種乳剤は、ハロゲン化銀粒子の全投影面積の90%
以上が最大隣接辺比が1.0〜2.0の六角平板粒子よ
り成り、六角平板粒子の平均厚さ0.064μm、平均
粒径(円直径換算)0.595μmであることを電子顕
微鏡にて確認した。又、厚さの変動係数は40%、双晶
面間距離の変動係数は42%であった。After completion of the addition, the pH was adjusted to 6 with a 3% aqueous potassium hydroxide solution, and immediately desalting and washing were performed.
This seed emulsion accounts for 90% of the total projected area of silver halide grains.
The electron microscope shows that the hexagonal tabular grains having a maximum adjacent side ratio of 1.0 to 2.0 as described above were formed, and the average thickness of the hexagonal tabular grains was 0.064 μm and the average grain size (in terms of circular diameter) was 0.595 μm. Confirmed. The variation coefficient of the thickness was 40%, and the variation coefficient of the distance between twin planes was 42%.
【0089】〈Em−4の調製〉種乳剤−IIと以下に示
す3種の溶液を用い、平板状純臭化銀乳剤Em−4を調
製した。<Preparation of Em-4> A tabular pure silver bromide emulsion Em-4 was prepared using Seed Emulsion-II and the following three kinds of solutions.
【0090】 A4 オセインゼラチン 34.03g 界面活性剤SA−1の10%エタノール水溶液 2.25ml 種乳剤−II 1.218モル相当 水で 3150mlに仕上げる B4 臭化カリウム 1747g 水で 3669mlに仕上げる C4 硝酸銀 2493g 水で 4193mlに仕上げる 反応容器内で溶液A4を60℃に保ちながら激しく撹拌
し、そこに溶液B4と溶液C4の全量を100分かけて
同時混合法にて添加した。この間、pHは5.8に、p
Agは8.8に終始保った。ここで溶液B4と溶液C4
の添加速度は臨界成長速度に見合ったように時間に対し
て関数様に変化させた。即ち、成長している種粒子以外
に小粒子の発生がないように、又、オストワルド熟成に
より多分散化しないように適切な添加速度で添加した。A4 Ossein gelatin 34.03 g 10% aqueous solution of surfactant SA-1 in ethanol 2.25 ml Seed emulsion-II 1.218 mol equivalent Equivalent to 3150 ml with water B4 1747 g Potassium bromide 1369 g with water C4 silver nitrate Finishing to 4193 ml with 2493 g water The solution A4 was vigorously stirred in a reaction vessel while maintaining the temperature at 60 ° C., and the total amount of the solution B4 and the solution C4 was added thereto over 100 minutes by a double jet method. During this time, the pH was adjusted to 5.8 and p
Ag was kept at 8.8 throughout. Here, solution B4 and solution C4
The addition rate was varied as a function of time to match the critical growth rate. That is, they were added at an appropriate addition rate so as to prevent generation of small particles other than the growing seed particles and to prevent polydispersion by Ostwald ripening.
【0091】添加終了後、この乳剤を40℃に冷却し、
凝集高分子剤としてフェニルカルバモイル基変性ゼラチ
ン(置換率90%)の13.8%(重量)の水溶液18
00mlを添加し3分間撹拌した。その後、酢酸56%
(重量)水溶液を添加して乳剤のpHを4.6に調整
し、3分間撹拌した後、20分間静置させデカンテーシ
ョンにより上澄み液を排水した。その後、40℃の蒸留
水9.0リットルを加え撹拌静置後、上澄み液を排水し
更に蒸留水11.25リットルを加え、撹拌静置後、上
澄み液を排水した。続いてゼラチン水溶液と炭酸ナトリ
ウム10%(重量)水溶液を加えて、pHが5.80に
なるよう調整し、50℃で30分間撹拌し再分散した。After the addition was completed, the emulsion was cooled to 40 ° C.
13.8% (by weight) aqueous solution of phenylcarbamoyl group-modified gelatin (substitution rate 90%) as an aggregating polymer agent 18
00 ml was added and stirred for 3 minutes. Then 56% acetic acid
(Weight) An aqueous solution was added to adjust the pH of the emulsion to 4.6, and the mixture was stirred for 3 minutes, allowed to stand for 20 minutes, and the supernatant was drained by decantation. Thereafter, 9.0 liters of distilled water at 40 ° C. was added, and the mixture was stirred and allowed to stand. The supernatant was drained, and 11.25 liters of distilled water was further added. After stirring and allowed to stand, the supernatant was drained. Subsequently, an aqueous gelatin solution and a 10% (by weight) aqueous sodium carbonate solution were added to adjust the pH to 5.80, followed by stirring at 50 ° C. for 30 minutes to redisperse.
【0092】再分散後、40℃にてpHを5.80、p
Agを8.06に調整した。得られた乳剤を電子顕微鏡
観察したところ、平均粒径1.11μm、平均厚さ0.
25μm、平均アスペクト比約4.5、粒径分布の広さ
18.1%の平板状粒子であった。又、双晶面間距離
(a)の平均は0.020μm、(a)の変動係数は3
2%であった。After redispersion, the pH was adjusted to 5.80 and p
Ag was adjusted to 8.06. When the obtained emulsion was observed with an electron microscope, the average particle diameter was 1.11 μm and the average thickness was 0.1 μm.
Tabular grains having a size of 25 μm, an average aspect ratio of about 4.5, and a particle size distribution of 18.1% were obtained. The average of the twin plane distance (a) is 0.020 μm, and the variation coefficient of (a) is 3
2%.
【0093】次に上記乳剤Em−1〜4を用いて、本発
明の硫黄化合物(硫黄増感剤)による増感効果を次のよ
うにして調べた。Next, the sensitizing effects of the sulfur compounds (sulfur sensitizers) of the present invention were examined using the above emulsions Em-1 to Em-4 as follows.
【0094】即ち、各乳剤を60℃にした後に、所定量
の分光増感色素を固体微粒子状の分散物として添加後、
アデニン、チオシアン酸アンモニウム、表1に示す増感
剤を加え、更に60分後に沃化銀微粒子乳剤を加え、総
計2時間の化学熟成を施した。化学熟成終了時に安定剤
として4−ヒドロキシ−6−メチル−1,3,3a,7
−テトラザインデン(ST−1)の所定量を添加した。
これら添加剤とその添加量(AgX1モル当たり)を下
記に示す。That is, after each emulsion was heated to 60 ° C., a predetermined amount of spectral sensitizing dye was added as a dispersion of solid fine particles.
Adenine, ammonium thiocyanate and the sensitizers shown in Table 1 were added, and after 60 minutes, a silver iodide fine grain emulsion was added, followed by a total of 2 hours of chemical ripening. At the end of chemical ripening, 4-hydroxy-6-methyl-1,3,3a, 7 is used as a stabilizer.
-A predetermined amount of tetrazaindene (ST-1) was added.
The additives and their amounts (per mole of AgX) are shown below.
【0095】 分光増感色素(SD−1) 2.0mg 分光増感色素(SD−2) 120mg アデニン(安定剤) 15mg チオシアン酸アンモニウム 95mg 水溶性金化合物(表1記載) 4.0×10-4モル/モル銀 硫黄化合物(表1記載) 5.0×10-4モル/モル銀 沃化銀微粒子 280mg 安定剤(ST−1) 50mgSpectral sensitizing dye (SD-1) 2.0 mg Spectral sensitizing dye (SD-2) 120 mg Adenine (stabilizer) 15 mg Ammonium thiocyanate 95 mg Water-soluble gold compound (described in Table 1) 4.0 × 10 − 4 mol / mol silver Sulfur compound (described in Table 1) 5.0 × 10 -4 mol / mol silver fine silver iodide particles 280 mg Stabilizer (ST-1) 50 mg
【0096】[0096]
【化9】 Embedded image
【0097】分光増感色素の固体微粒子状分散物は、特
開平5−297496号に記載の方法に準じて調製し
た。即ち分光増感色素の所定量を予め27℃に調温した
水に加え、高速撹拌機(ディゾルバー)で3,500r
pmにて30〜120分間に亘って撹拌することによっ
て得た。The dispersion of the solid fine particles of the spectral sensitizing dye was prepared according to the method described in JP-A-5-297496. That is, a predetermined amount of the spectral sensitizing dye is added to water whose temperature has been previously adjusted to 27 ° C., and 3,500 r.
Obtained by stirring at pm for 30-120 minutes.
【0098】尚、上記の沃化銀微粒子の添加により、乳
剤Em−4中に含有されるハロゲン化銀粒子の最表面の
平均沃度含有率は約4モル%であった。The average iodide content of the outermost surface of the silver halide grains contained in the emulsion Em-4 was about 4 mol% by the addition of the silver iodide fine grains.
【0099】このようにして増感を施した乳剤に、後記
の添加剤を加えて乳剤層塗布液とし、又、同時に保護層
塗布液も調製した。To the emulsion thus sensitized, the following additives were added to prepare an emulsion layer coating solution, and at the same time, a protective layer coating solution was prepared.
【0100】尚、支持体は、厚みが175μmで濃度
0.15に青色着色したX線用のポリエチレンテレフタ
レートフィルムベースの両面に、グリシジルメタクリレ
ート・メチルアクリレート・ブチルメタクリレート共重
合体(50:10:40wt%)の濃度が10wt%に
なるように希釈して得た共重合体水性分散液を分散させ
て下引液として塗布したものを用いた。The support was a glycidyl methacrylate / methyl acrylate / butyl methacrylate copolymer (50:10:40 wt.) On both sides of a polyethylene terephthalate film base for X-rays having a thickness of 175 μm and a blue color of 0.15. %) Was dispersed so as to have a concentration of 10% by weight, and an aqueous dispersion of the copolymer was dispersed and used as an undercoat liquid.
【0101】下記染料層を支持体の両面上に塗設し、次
に乳剤層塗布液と保護層塗布液を下記の所定塗布量にな
るよう、2台のスライドホッパー型コーターを用いて両
面同時塗布を行い、乾燥して感光材料試料1〜16を作
製した。The following dye layers are coated on both sides of the support, and then the emulsion layer coating solution and the protective layer coating solution are simultaneously coated on both sides using two slide hopper coaters so that the following coating amounts are obtained. Coating and drying were performed to produce photosensitive material samples 1 to 16.
【0102】尚、各層の添加剤量は試料1m2当たりの
付量(片面分)を示す。又、塗布銀量は片面分として
1.6g/m2になるよう調整した。The amount of the additive in each layer indicates the amount (one side) per 1 m 2 of the sample. The amount of silver applied was adjusted so as to be 1.6 g / m 2 on one side.
【0103】 第1層(染料層) 染料 F−1(固体微粒子分散体) 180mg ゼラチン 0.2g 界面活性剤(SA−2) 5mg ラテックス(L) 0.2g 硬膜剤(H−1) 5mg コロイダルシリカ(平均粒径0.014μm) 10mg ホルムアルデヒド(硬膜剤) 2mg 第2層(乳剤層) 上記で得た各々の乳剤に下記の各種添加剤を加えた。First layer (dye layer) Dye F-1 (solid fine particle dispersion) 180 mg Gelatin 0.2 g Surfactant (SA-2) 5 mg Latex (L) 0.2 g Hardener (H-1) 5 mg Colloidal silica (average particle size: 0.014 μm) 10 mg Formaldehyde (hardener) 2 mg Second layer (emulsion layer) The following various additives were added to each emulsion obtained above.
【0104】 添加剤(T−1) 0.5mg 添加剤(T−2) 5mg t−ブチル−カテコール 130mg ポリビニルピロリドン(分子量10,000) 35mg スチレン−無水マレイン酸共重合体 80mg ポリスチレンスルホン酸ナトリウム 80mg トリメチロールプロパン 350mg ジエチレングリコール 50mg ニトロフェニル−トリフェニル−ホスホニウムクロリド 20mg レゾルシン−4−スルホン酸アンモニウム 500mg 2−メルカプトベンゾイミダゾール−5−スルホン酸ナトリウム 5mg 添加剤(T−3) 0.5mg C4H9OCH2CH(OH)CH2N(CH2COOH)2 350mg 化合物(ST−2) 5mg 化合物(ST−3) 0.2mg 化合物(ST−4) 5mg 化合物(ST−5) 0.2mg コロイダルシリカ 0.5g ラテックス(L) 0.2g デキストリン(平均分子量1000) 0.2g 5−メチルベンゾトリアゾール 0.7mg ただし、ゼラチンとして1.0g/m2になるように調
整した。Additive (T-1) 0.5 mg Additive (T-2) 5 mg t-butyl-catechol 130 mg polyvinylpyrrolidone (molecular weight 10,000) 35 mg styrene-maleic anhydride copolymer 80 mg sodium polystyrene sulfonate 80 mg Trimethylolpropane 350 mg Diethylene glycol 50 mg Nitrophenyl-triphenyl-phosphonium chloride 20 mg Resorcin-4-ammonium ammonium sulfonate 500 mg 2-Mercaptobenzimidazole-5-sodium sulfonate 5 mg Additive (T-3) 0.5 mg C 4 H 9 OCH 2 CH (OH) CH 2 N (CH 2 COOH) 2 350mg compound (ST-2) 5mg compound (ST-3) 0.2mg compound (ST-4) 5mg compound (ST-5) 0.2 g Colloidal silica 0.5g Latex (L) 0.2 g Dextrin (average molecular weight 1000) 0.2 g 5-methylbenzotriazole 0.7mg however, was adjusted to 1.0 g / m 2 as gelatin.
【0105】 第3層(保護層) ゼラチン 0.8g 安定剤(ST−1) 20mg PMMAから成るマット剤(面積平均粒径7.0μm) 50mg ホルムアルデヒド(硬膜剤) 20mg 硬膜剤(H−1) 10mg グリオキザール(硬膜剤) 36mg ラテックス(L) 0.2g ポリアクリルアミド(平均分子量10000) 0.1g ポリアクリル酸ナトリウム 30mg 添加剤(SI−1) 20mg 界面活性剤(SA−3) 12mg 界面活性剤(SA−4) 2mg 界面活性剤(SA−5) 7mg 添加剤(T−4) 15mg C11H23CONH(CH2CH2O)5H(界面活性剤) 50mg 界面活性剤(SA−7) 5mg C9F19O(CH2CH2O)11H 3mg C8F17SO2N(CH2CH2O)15H 2mg C8F17SO2(C3H7)N(CH2CH2O)4(CH2)4SO3Na1mg SA−2:ドデシルベンゼンスルホン酸ナトリウム H−1:2,4−ジクロロ−6−ヒドロキシ−s−トリ
アジン・ナトリウム T−2:2,6−ジ(ヒドロキシアミノ)−4−ジエチ
ルアミノ−s−トリアジン ST−2:1−(3−スルホフェニル)−5−メルカプ
トテトラゾール・ナトリウム塩 ST−4:1−(3−カルボキシフェニル)−5−メル
カプトテトラゾール ST−5:2,6−ジメルカプト−4−アニリノ−s−
トリアジン・モノナトリウム PMMA:ポリメチルメタクリレート SA−4:p−ノニルフェノール・エチレンオキシド1
2モル付加物 SA−5:スルホ琥珀酸ジ(2,2,3,3,4,4,
5,5,6,6,7,7−ドデシルフルオロヘプチル)
ナトリウム塩 SA−7:スルホ琥珀酸ジ(2−エチルヘキシル)ナト
リウム塩Third layer (protective layer) Gelatin 0.8 g Stabilizer (ST-1) 20 mg Matting agent composed of PMMA (area average particle size 7.0 μm) 50 mg Formaldehyde (hardening agent) 20 mg Hardening agent (H- 1) 10 mg Glyoxal (hardener) 36 mg Latex (L) 0.2 g Polyacrylamide (average molecular weight 10,000) 0.1 g Sodium polyacrylate 30 mg Additive (SI-1) 20 mg Surfactant (SA-3) 12 mg Interface Surfactant (SA-4) 2 mg Surfactant (SA-5) 7 mg Additive (T-4) 15 mg C 11 H 23 CONH (CH 2 CH 2 O) 5 H (surfactant) 50 mg Surfactant (SA) -7) 5 mg C 9 F 19 O (CH 2 CH 2 O) 11 H 3 mg C 8 F 17 SO 2 N (CH 2 CH 2 O) 15 H 2 mg C 8 F 17 SO 2 (C 3 H 7) N (CH 2 CH 2 O) 4 (CH 2) 4 SO 3 Na1mg SA-2: Sodium dodecylbenzenesulfonate H-1: 2,4-dichloro-6-hydroxy -s- Triazine sodium T-2: 2,6-di (hydroxyamino) -4-diethylamino-s-triazine ST-2: 1- (3-sulfophenyl) -5-mercaptotetrazole sodium salt ST-4: 1- (3-carboxyphenyl) -5-mercaptotetrazole ST-5: 2,6-dimercapto-4-anilino-s-
Triazine / monosodium PMMA: polymethyl methacrylate SA-4: p-nonylphenol / ethylene oxide 1
2-mol adduct SA-5: sulfosuccinate di (2,2,3,3,4,4,
5,5,6,6,7,7-dodecylfluoroheptyl)
Sodium salt SA-7: di (2-ethylhexyl) sulfosuccinate sodium salt
【0106】[0106]
【化10】 Embedded image
【0107】[0107]
【化11】 Embedded image
【0108】次に、上述の如くして得た各試料を、それ
ぞれ2種類の条件下(条件A:23℃・55%RH、条
件B:40℃・80%RH)に5日間保存した後に、写
真特性を評価した。Next, each sample obtained as described above was stored under two kinds of conditions (condition A: 23 ° C./55% RH, condition B: 40 ° C./80% RH) for 5 days, The photographic characteristics were evaluated.
【0109】評価方法は、試料を2枚の増感紙KO−2
50(コニカ社製)で挟み、アルミウエッジを介して管
電圧80kVp、管電流100mA、0.05秒間のX
線を照射し露光した。次いで、自動現像機SRX−50
2(コニカ社製)を用い、下記処方の現像液及び定着液
で処理した。The evaluation method was as follows: two samples of intensifying screen KO-2
50 (manufactured by Konica Corp.), and a tube voltage of 80 kVp, a tube current of 100 mA, and an X of 0.05 second through an aluminum wedge.
A line was irradiated and exposed. Next, the automatic developing machine SRX-50
2 (manufactured by Konica Corp.) and processed with a developer and a fixer having the following formulation.
【0110】 (現像液処方)Part−A (12リットル仕上げ用) 水酸化カリウム 450g 亜硫酸カリウム(50%溶液) 2280g ジエチレントリアミン五酢酸 120g 重炭酸水素ナトリウム 132g 5−メチルベンゾトリアゾール 1.2g 1−フェニル−5−メルカプトテトラゾール 0.2g ハイドロキノン 340g 水を加えて 5000mlに仕上げるPart−B (12リットル仕上げ用) 氷酢酸 170g トリエチレングリコール 185g 1−フェニル−3−ピラゾリドン(フェニドン) 22g 5−ニトロインダゾール 0.4gスターター 氷酢酸 120g 臭化カリウム 225g 水を加えて 1リットルに仕上げる (定着液処方)Part−A (18リットル仕上げ用) チオ硫酸アンモニウム(70wt/vol%) 6000g 亜硫酸ナトリウム 110g 酢酸ナトリウム・3水塩 450g 枸櫞酸ナトリウム 50g グルコン酸 70g 1−(N,N−ジメチルアミノ)エチル−5−メルカプトテトラゾール 18gPart−B 硫酸アルミニウム 800g 現像液の調製は、水約5リットルにPartA及びPa
rtBを同時添加し、撹拌・溶解しながら水を加えて1
2リットルに仕上げ、氷酢酸でpHを10.40に調整
した。これを現像液とする。(Developer formulation) Part-A (for finishing 12 liters) Potassium hydroxide 450 g Potassium sulfite (50% solution) 2280 g Diethylenetriaminepentaacetic acid 120 g Sodium bicarbonate 132 g 5-Methylbenzotriazole 1.2 g 1-phenyl- 5-mercaptotetrazole 0.2 g hydroquinone 340 g Add water to make 5000 ml Part-B (for finishing 12 liters) Glacial acetic acid 170 g Triethylene glycol 185 g 1-Phenyl-3-pyrazolidone (phenidone) 22 g 5-Nitroindazole 0.4 g Starter Glacial acetic acid 120 g Potassium bromide 225 g Add water to make up to 1 liter (fixer solution formulation) Part-A (for finishing 18 liters) Ammonium thiosulfate (70 wt / vo) 1%) 6000 g sodium sulfite 110 g sodium acetate trihydrate 450 g sodium citrate 50 g gluconic acid 70 g 1- (N, N-dimethylamino) ethyl-5-mercaptotetrazole 18 g Part-B aluminum sulfate 800 g , Part A and Pa in about 5 liters of water
rtB was added at the same time, and water was added while stirring and dissolving.
Finished to 2 liters and adjusted pH to 10.40 with glacial acetic acid. This is used as a developer.
【0111】この現像液1リットルに対し前記スタータ
ーを20ml/リットル添加し、pHを10.26に調
整し使用液とする。The starter was added to 1 liter of the developing solution at a rate of 20 ml / liter to adjust the pH to 10.26 to prepare a working solution.
【0112】定着液の調製は、水約5リットルにPar
tA及びPartBを同時添加し、撹拌・溶解しながら
水を加えて18リットルに仕上げ、硫酸と水酸化ナトリ
ウムを用いてpHを4.4に調整した。これを定着補充
液とする。The fixer was prepared by adding Par.
tA and PartB were added at the same time, water was added while stirring and dissolving to make up to 18 liters, and the pH was adjusted to 4.4 with sulfuric acid and sodium hydroxide. This is used as a fixing replenisher.
【0113】尚、処理温度は、現像35℃、定着33
℃、水洗20℃、乾燥50℃、処理時間はdry to
dryで45秒である。The processing temperature was 35 ° C. for development and 33 ° for fixing.
℃, water washing 20 ℃, drying 50 ℃, treatment time is dry to
The dry time is 45 seconds.
【0114】処理後、感度の測定を行った。感度はカブ
リ+0.5の濃度を与える露光量の逆数で表し、試料1
の保存条件Aの感度を100とした時の相対感度で示し
た。得られた結果を表1に示す。After the treatment, the sensitivity was measured. The sensitivity is represented by the reciprocal of the exposure amount that gives a density of fog + 0.5,
The relative sensitivity when the sensitivity under the storage condition A was 100. Table 1 shows the obtained results.
【0115】[0115]
【表1】 [Table 1]
【0116】[0116]
【化12】 Embedded image
【0117】表1から明らかなように、本発明に係る試
料は、ハロゲン化銀粒子の形態によらずカブリが低く抑
えられた高感度が得られ、かつ高温・高湿下で保存され
ても(保存条件B)感度及びカブリの変動が少なく、優
れている。As is evident from Table 1, the sample according to the present invention provides high sensitivity with low fog regardless of the form of silver halide grains, and can be stored at high temperature and high humidity. (Storage condition B) The variation in sensitivity and fog is small and excellent.
【0118】[0118]
【発明の効果】本発明により、カブリを伴わずに感度が
高められ、かつ保存安定性に優れたハロゲン化銀感光材
料を提供することができた。According to the present invention, it is possible to provide a silver halide light-sensitive material having improved sensitivity without fog and excellent storage stability.
フロントページの続き (72)発明者 香川 宣明 東京都日野市さくら町1番地コニカ株式会 社内Continued on the front page (72) Inventor Noriaki Kagawa 1 Konica Stock Company, Sakuracho, Hino-shi, Tokyo
Claims (1)
ゲン化銀乳剤層を有するハロゲン化銀写真感光材料にお
いて、該ハロゲン化銀乳剤層の少なくとも1層が、下記
一般式(I)で示される化合物の少なくとも1種によっ
て増感されたハロゲン化銀粒子を含むことを特徴とする
ハロゲン化銀写真感光材料。 【化1】 〔式中、Aはメルカプト基が置換した含窒素複素環残
基、環構成原子として窒素原子を4〜5個含む含窒素複
素環残基、トリアジン環残基又はベンゾトリアゾール環
残基を表し、R1、R2及びR3は各々、水素原子、アル
キル基、アルケニル基、アルキニル基、アリール基又は
複素環基を表す。又、R2とR3が結合して複素環を形成
してもよい。〕1. A silver halide photographic material having at least one light-sensitive silver halide emulsion layer on a support, wherein at least one of the silver halide emulsion layers is represented by the following general formula (I). A silver halide photographic material comprising silver halide grains sensitized by at least one compound selected from the group consisting of: Embedded image [In the formula, A represents a nitrogen-containing heterocyclic residue substituted with a mercapto group, a nitrogen-containing heterocyclic residue containing 4 to 5 nitrogen atoms as ring constituent atoms, a triazine ring residue or a benzotriazole ring residue, R 1 , R 2 and R 3 each represent a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, an aryl group or a heterocyclic group. R 2 and R 3 may combine to form a heterocyclic ring. ]
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP866897A JPH10206995A (en) | 1997-01-21 | 1997-01-21 | Silver halide photographic sensitive material |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP866897A JPH10206995A (en) | 1997-01-21 | 1997-01-21 | Silver halide photographic sensitive material |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH10206995A true JPH10206995A (en) | 1998-08-07 |
Family
ID=11699322
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP866897A Pending JPH10206995A (en) | 1997-01-21 | 1997-01-21 | Silver halide photographic sensitive material |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH10206995A (en) |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2004108729A1 (en) * | 2003-06-03 | 2006-07-20 | 日本化薬株式会社 | [1,2,4] Triazolo [1,5-a] pyrimidin-2-ylurea derivatives and uses thereof |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
US8901133B2 (en) | 2010-11-10 | 2014-12-02 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8969363B2 (en) | 2011-07-19 | 2015-03-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8980899B2 (en) | 2009-10-16 | 2015-03-17 | The Regents Of The University Of California | Methods of inhibiting Ire1 |
US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
US9056877B2 (en) | 2011-07-19 | 2015-06-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9096611B2 (en) | 2008-07-08 | 2015-08-04 | Intellikine Llc | Kinase inhibitors and methods of use |
US9115141B2 (en) | 2011-08-29 | 2015-08-25 | Infinity Pharmaceuticals, Inc. | Substituted isoquinolinones and methods of treatment thereof |
US9181221B2 (en) | 2010-05-21 | 2015-11-10 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
US9290497B2 (en) | 2011-01-10 | 2016-03-22 | Infinity Pharmaceuticals, Inc. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
US9296742B2 (en) | 2008-09-26 | 2016-03-29 | Intellikine Llc | Heterocyclic kinase inhibitors |
US9295673B2 (en) | 2011-02-23 | 2016-03-29 | Intellikine Llc | Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof |
US9315505B2 (en) | 2009-05-07 | 2016-04-19 | Intellikine Llc | Heterocyclic compounds and uses thereof |
US9321772B2 (en) | 2011-09-02 | 2016-04-26 | The Regents Of The University Of California | Substituted pyrazolo[3,4-D]pyrimidines and uses thereof |
US9359365B2 (en) | 2013-10-04 | 2016-06-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9359349B2 (en) | 2007-10-04 | 2016-06-07 | Intellikine Llc | Substituted quinazolines as kinase inhibitors |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
US9493467B2 (en) | 2006-04-04 | 2016-11-15 | The Regents Of The University Of California | PI3 kinase antagonists |
US9512125B2 (en) | 2004-11-19 | 2016-12-06 | The Regents Of The University Of California | Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents |
US9527847B2 (en) | 2012-06-25 | 2016-12-27 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
US9629843B2 (en) | 2008-07-08 | 2017-04-25 | The Regents Of The University Of California | MTOR modulators and uses thereof |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9775844B2 (en) | 2014-03-19 | 2017-10-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9822131B2 (en) | 2008-01-04 | 2017-11-21 | Intellikine Llc | Certain chemical entities, compositions and methods |
US10131668B2 (en) | 2012-09-26 | 2018-11-20 | The Regents Of The University Of California | Substituted imidazo[1,5-a]pYRAZINES for modulation of IRE1 |
US10160761B2 (en) | 2015-09-14 | 2018-12-25 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same |
US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US11110096B2 (en) | 2014-04-16 | 2021-09-07 | Infinity Pharmaceuticals, Inc. | Combination therapies |
US11147818B2 (en) | 2016-06-24 | 2021-10-19 | Infinity Pharmaceuticals, Inc. | Combination therapies |
-
1997
- 1997-01-21 JP JP866897A patent/JPH10206995A/en active Pending
Cited By (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4698419B2 (en) * | 2003-06-03 | 2011-06-08 | 日本化薬株式会社 | [1,2,4] Triazolo [1,5-a] pyrimidin-2-ylurea derivatives and uses thereof |
JPWO2004108729A1 (en) * | 2003-06-03 | 2006-07-20 | 日本化薬株式会社 | [1,2,4] Triazolo [1,5-a] pyrimidin-2-ylurea derivatives and uses thereof |
US9512125B2 (en) | 2004-11-19 | 2016-12-06 | The Regents Of The University Of California | Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents |
US9493467B2 (en) | 2006-04-04 | 2016-11-15 | The Regents Of The University Of California | PI3 kinase antagonists |
US9359349B2 (en) | 2007-10-04 | 2016-06-07 | Intellikine Llc | Substituted quinazolines as kinase inhibitors |
US11433065B2 (en) | 2008-01-04 | 2022-09-06 | Intellikine Llc | Certain chemical entities, compositions and methods |
US9822131B2 (en) | 2008-01-04 | 2017-11-21 | Intellikine Llc | Certain chemical entities, compositions and methods |
US9216982B2 (en) | 2008-01-04 | 2015-12-22 | Intellikine Llc | Certain chemical entities, compositions and methods |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
US9655892B2 (en) | 2008-01-04 | 2017-05-23 | Intellikine Llc | Certain chemical entities, compositions and methods |
US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
US9637492B2 (en) | 2008-03-14 | 2017-05-02 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
US9828378B2 (en) | 2008-07-08 | 2017-11-28 | Intellikine Llc | Kinase inhibitors and methods of use |
US9096611B2 (en) | 2008-07-08 | 2015-08-04 | Intellikine Llc | Kinase inhibitors and methods of use |
US9629843B2 (en) | 2008-07-08 | 2017-04-25 | The Regents Of The University Of California | MTOR modulators and uses thereof |
US9790228B2 (en) | 2008-09-26 | 2017-10-17 | Intellikine Llc | Heterocyclic kinase inhibitors |
US9296742B2 (en) | 2008-09-26 | 2016-03-29 | Intellikine Llc | Heterocyclic kinase inhibitors |
US9315505B2 (en) | 2009-05-07 | 2016-04-19 | Intellikine Llc | Heterocyclic compounds and uses thereof |
US9206182B2 (en) | 2009-07-15 | 2015-12-08 | Intellikine Llc | Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof |
US9522146B2 (en) | 2009-07-15 | 2016-12-20 | Intellikine Llc | Substituted Isoquinolin-1(2H)-one compounds, compositions, and methods thereof |
US8980899B2 (en) | 2009-10-16 | 2015-03-17 | The Regents Of The University Of California | Methods of inhibiting Ire1 |
US9738644B2 (en) | 2010-05-21 | 2017-08-22 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
US9181221B2 (en) | 2010-05-21 | 2015-11-10 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
US9388183B2 (en) | 2010-11-10 | 2016-07-12 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8901133B2 (en) | 2010-11-10 | 2014-12-02 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9290497B2 (en) | 2011-01-10 | 2016-03-22 | Infinity Pharmaceuticals, Inc. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
US10550122B2 (en) | 2011-01-10 | 2020-02-04 | Infinity Pharmaceuticals, Inc. | Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one and methods of use thereof |
US11312718B2 (en) | 2011-01-10 | 2022-04-26 | Infinity Pharmaceuticals, Inc. | Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one |
USRE46621E1 (en) | 2011-01-10 | 2017-12-05 | Infinity Pharmaceuticals, Inc. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
US9840505B2 (en) | 2011-01-10 | 2017-12-12 | Infinity Pharmaceuticals, Inc. | Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof |
US9295673B2 (en) | 2011-02-23 | 2016-03-29 | Intellikine Llc | Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof |
US9056877B2 (en) | 2011-07-19 | 2015-06-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9718815B2 (en) | 2011-07-19 | 2017-08-01 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9605003B2 (en) | 2011-07-19 | 2017-03-28 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8969363B2 (en) | 2011-07-19 | 2015-03-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9546180B2 (en) | 2011-08-29 | 2017-01-17 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9115141B2 (en) | 2011-08-29 | 2015-08-25 | Infinity Pharmaceuticals, Inc. | Substituted isoquinolinones and methods of treatment thereof |
US9321772B2 (en) | 2011-09-02 | 2016-04-26 | The Regents Of The University Of California | Substituted pyrazolo[3,4-D]pyrimidines and uses thereof |
US9895373B2 (en) | 2011-09-02 | 2018-02-20 | The Regents Of The University Of California | Substituted pyrazolo[3,4-D]pyrimidines and uses thereof |
US9255108B2 (en) | 2012-04-10 | 2016-02-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9527847B2 (en) | 2012-06-25 | 2016-12-27 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
US10822340B2 (en) | 2012-09-26 | 2020-11-03 | The Regents Of The University Of California | Substituted imidazolopyrazine compounds and methods of using same |
US11613544B2 (en) | 2012-09-26 | 2023-03-28 | The Regents Of The University Of California | Substituted imidazo[1,5-a]pyrazines for modulation of IRE1 |
US10131668B2 (en) | 2012-09-26 | 2018-11-20 | The Regents Of The University Of California | Substituted imidazo[1,5-a]pYRAZINES for modulation of IRE1 |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US10329299B2 (en) | 2013-10-04 | 2019-06-25 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9359365B2 (en) | 2013-10-04 | 2016-06-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9828377B2 (en) | 2013-10-04 | 2017-11-28 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US10675286B2 (en) | 2014-03-19 | 2020-06-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US11541059B2 (en) | 2014-03-19 | 2023-01-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9775844B2 (en) | 2014-03-19 | 2017-10-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US11110096B2 (en) | 2014-04-16 | 2021-09-07 | Infinity Pharmaceuticals, Inc. | Combination therapies |
US11944631B2 (en) | 2014-04-16 | 2024-04-02 | Infinity Pharmaceuticals, Inc. | Combination therapies |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
US10253047B2 (en) | 2014-10-03 | 2019-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US10941162B2 (en) | 2014-10-03 | 2021-03-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US11247995B2 (en) | 2015-09-14 | 2022-02-15 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same |
US10160761B2 (en) | 2015-09-14 | 2018-12-25 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same |
US11939333B2 (en) | 2015-09-14 | 2024-03-26 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same |
US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US11147818B2 (en) | 2016-06-24 | 2021-10-19 | Infinity Pharmaceuticals, Inc. | Combination therapies |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH10206995A (en) | Silver halide photographic sensitive material | |
JPS6035055B2 (en) | silver halide photographic emulsion | |
JPS5851252B2 (en) | silver halide photographic emulsion | |
US4521508A (en) | Silver halide photographic light-sensitive materials | |
JPS61170732A (en) | Silver halide photographic sensitive material | |
JP3042712B2 (en) | Selenium and iridium doped emulsions | |
JP2838563B2 (en) | Silver halide photographic material | |
JPH08179465A (en) | Silver halide photographic sensitive material and development processing method | |
JPS6046417B2 (en) | Spectrally sensitized silver halide photographic emulsion | |
JPS63199347A (en) | High-sensitivity silver halide photographic sensitive material having improved sharpness | |
JP2864059B2 (en) | Silver halide photographic emulsions and photographic materials | |
JP2604278B2 (en) | Chemical sensitization of silver halide emulsion | |
JP2739389B2 (en) | Silver halide photographic material | |
JP2873852B2 (en) | Silver halide photographic material | |
JP2709756B2 (en) | Silver halide photographic material | |
JP2796453B2 (en) | Silver halide photographic material | |
JPH08328188A (en) | Silver halide photographic sensitive material | |
JP3160790B2 (en) | Photosensitive silver halide photographic emulsion, silver halide photographic material, and method of processing silver halide photographic material | |
JPH08179467A (en) | Silver halide photographic sensitive material and its development processing method | |
JPH10197979A (en) | Silver halide photosensitive material | |
JPH03288843A (en) | Production of silver halide photographic sensitive material | |
JP2796454B2 (en) | Silver halide photographic material | |
JP3421501B2 (en) | Silver halide photographic materials | |
JPH0457046A (en) | Silver halide photographic sensitive material | |
JPS62275242A (en) | Silver halide photosensitive material for direct positive printing |